Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
Back to Home
E

ELAN

NYSE

Elanco Animal Health Inc

Latest disclosureOctober 6, 2026
Insider score Why 63?
63/ 100
Qualifying buys · 30d
$0

7 purchases · 0 sales

Price by TradingViewDelayed quote from TradingView, for viewing only. It does not power Whale Atlas scores or alerts. If the quote does not load, open the TradingView link.

Insider transactions 74

Limited filing history
All74Buying7Selling0Other67
Filters

Last 30 daysNo qualifying insider buying. No qualifying insider sales.

7 of 74 trades · March 31, 2026 – October 2, 2026Incomplete history: this shows the filings imported so far, not every filing ever made. Dates are trade dates. Filters affect this table only.

Showing the first 6 of 7 trades on this page.

Purchase disclosed

Lawrence Erik Kurzius

Director

Common Stock

Reported value
$935.92K
Reported price
$23.398 / share
Traded August 20, 2026Filed August 21, 2026SEC filing
Purchase disclosed

Shiv O.'Neill

GC AND CORP SEC

Common Stock

Reported value
$94.27K
Reported price
$23.58 / share
Traded August 18, 2026Filed August 18, 2026SEC filing
Purchase disclosed

Michael J. Harrington

Director

Common Stock

Reported value
$109.1K
Reported price
$21.82 / share
Traded August 12, 2026Filed August 13, 2026SEC filing
Purchase disclosed

Robert M. VanHimbergen

EVP and CFO

Common Stock

Reported value
$96.93K
Reported price
$23.0776 / share
Traded August 7, 2026Filed August 10, 2026SEC filing
Purchase disclosed

Paul Herendeen

Director

Common Stock

Reported value
$236.85K
Reported price
$23.685 / share
Traded August 7, 2026Filed August 10, 2026SEC filing
Purchase disclosed

Rajeev A. Modi

SEE REMARKS

Common Stock

Reported value
$99.94K
Reported price
$20.35 / share
Traded May 15, 2026Filed May 19, 2026SEC filing
Purchase disclosed

Jeffrey N. Simmons

PRESIDENT, CEO AND DIRECTOR

Common Stock

Reported value
$99.84K
Reported price
$20.085 / share
Traded May 15, 2026Filed May 19, 2026SEC filing
Reporting insiderSecurity / transactionAmount / priceValueTraded / disclosedSource
DirectorCommon StockPurchase40,000$23.40 / share$935.92KAug 20Filed Aug 21 · 1d laterSEC filing
GC AND CORP SECCommon StockPurchase3,998$23.58 / share$94.27KAug 18Filed Aug 18 · 0d laterSEC filing
DirectorCommon StockPurchase5,000$21.82 / share$109.1KAug 12Filed Aug 13 · 1d laterSEC filing
EVP and CFOCommon StockPurchase4,200$23.08 / share$96.93KAug 7Filed Aug 10 · 3d laterSEC filing
DirectorCommon StockPurchase10,000$23.69 / share$236.85KAug 7Filed Aug 10 · 3d laterSEC filing
SEE REMARKSCommon StockPurchase4,911$20.35 / share$99.94KMay 15Filed May 19 · 4d laterSEC filing
PRESIDENT, CEO AND DIRECTORCommon StockPurchase4,971$20.09 / share$99.84KMay 15Filed May 19 · 4d laterSEC filing

Congress transactions 1

All Congress filings
Sale disclosed

Elanco Animal Health Incorporated Common Stock (ELAN) · Stock

The filing reports a sale for a spouse.

Valerie Hoyle official portraitValerie HoyleReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
September 23, 2025
Filed October 10, 2025 · 17d laterOriginal report
Explore furtherTechnical lab Company financials Test a strategy Compare company

Why this buying score?

Qualifying common-equity purchase value

$1,087,992 of common-equity purchase value after transaction-age decay across 180 days.

+25 pts

Distinct buying groups

7 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.

+20 pts

CEO purchase

Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.

+4 pts

CFO purchase

Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.

+6 pts

Material reported holdings increase

At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.

+8 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage
Source
SEC EDGAR · Form 4
Issuer CIK
0001739104
Latest public acceptance
Oct 6, 2026, 08:37 PM UTC
Score calculated
Oct 8, 2026, 12:09 AM UTC
Parser
form4-parser-1.5
Classifier
form4-classifier-1.1
Scoring methodology
insider-experimental-1.1
Availability
Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.